

Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable

Information for the public

Published: 11 September 2025

www.nice.org.uk

Enfortumab vedotin (Padcev) with pembrolizumab (Keytruda) is available on the NHS as a possible treatment for untreated unresectable or metastatic urothelial cancer in adults who can have platinum-based chemotherapy.

Unresectable means that the cancer cannot be removed by surgery and metastatic means that it has spread to other parts of the body.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on bladder cancer](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Action Bladder Cancer UK](#), 0300 302 0085
- [Fight Bladder Cancer](#), 01844 351621
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-7197-8